CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

In a report released on August 3, Luca Issi from RBC Capital maintained a Hold rating on Crispr Therapeutics AG, with a price target of $50.00. The...

RBC Capital Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pfizer (PFE), Crispr Therapeutics AG (CRSP) and Palv...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Wells Fargo analyst Yanan Zhu maintained a Hold rating on Crispr Therapeutics AG today and set a price target of $75.00. Zhu covers the Healthcare ...

Crispr Therapeutics AG (CRSP) Receives a Hold from Wells Fargo

In a report released yesterday, from Goldman Sachs maintained a Hold rating on Crispr Therapeutics AG, with a price target of $48.00. The company’s...

Crispr Therapeutics AG (CRSP) Receives a Hold from Goldman Sachs

Crispr Therapeutics ($CRSP) announced an update on their ongoing clinical study. Crispr Therapeutics (CRSP) is running an early stage trial to test...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CRSP	$53.99	-0.15%	739.72K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CRSP	$53.99	-0.1%	739.72K
3
4
5
6

CRSP

Get CRISPR Therapeutics AG Data in Excel

Get CRISPR Therapeutics AG Data in Excel